Advance Search
SUN Jun, LI Yongjun, SHEN Zhiyong, HUANG Honghua, ZHANG Weihua, JIANG Juan. Effect of transcatheter arterial chemoembolization associated with domestic CalliSpheres drug-loaded microspheres in treatment of patients with hepatic malignant tumor[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 10-13. DOI: 10.7619/jcmp.202008003
Citation: SUN Jun, LI Yongjun, SHEN Zhiyong, HUANG Honghua, ZHANG Weihua, JIANG Juan. Effect of transcatheter arterial chemoembolization associated with domestic CalliSpheres drug-loaded microspheres in treatment of patients with hepatic malignant tumor[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 10-13. DOI: 10.7619/jcmp.202008003
shu

Effect of transcatheter arterial chemoembolization associated with domestic CalliSpheres drug-loaded microspheres in treatment of patients with hepatic malignant tumor

  • 1. Department of Intervention;

  • 2. Department of Imaging, Nantong Tumor Hospital, Nantong, Jiangsu, 226361

More Information
  • Received Date: February 24, 2020
    Graphical Abstract
    • Abstract
  • Objective To compare the effect of transcatheter arterial chemoembolization associated with domestic CalliSpheres drug-loaded microspheres(DEB-TACE)and conventional transcatheter arterial chemoembolization(cTACE)in treatment of patients with hepatic malignant tumor. Methods A total of 88 patients with hepatic malignant tumor were selected and randomly divided into cTACE group(n=49)and DEB-TACE group(n=39)according to different surgical progran. The short-term efficacy and the incidence of acute adverse reactions were compared between the two groups. After 2 years of follow-up, the survival rate without tumor recurrence and total survival rate at time points of 0.5, 1, 1.5 and 2 years after operation were compared between the two groups. Results After treatment, the disease remission rate and disease control rate of DEB-TACE group were significantly higher than those of cTACE group(P<0.05). There was no significant difference in incidence of acute adverse reactions between the two groups(P>0.05). The survival rate without tumor recurrence and total survival rate in DEB-TACE group were significantly higher than those in cTACE group(P<0.05). Conclusion DEB-TACE can significantly improve the short-term effect, the survival rate without tumor recurrence and total survival rate of hepatic malignant tumor patients who can not be treated by surgery, and its safety is higher.
    • FullText(HTML)
    • References (17)
  • 中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J]. 中华放射学杂志, 2019, 53(4): 246-255.
    李家平, 滕皋军. 经肝动脉化疗栓塞术指南: 规范化与个体化并举[J]. 中华放射学杂志, 2019, 53(4): 241-242.
    王强, 龙晶. 中医药联合肝动脉栓塞术治疗原发性肝癌临床观察[J]. 湖北中医药大学学报, 2014, 16(3): 73-75.
    朱六玲, 蔡陈枫, 孟岩. TACE联合调强放疗对不可切除原发性肝癌的疗效研究[J]. 国际医学放射学杂志, 2019, 42(2): 149-153.
    颜綦先, 肖潇, 崔红莉, 等. 生物微球联合碘油经肝动脉栓塞化疗治疗原发性肝癌临床观察[J]. 实用肝脏病杂志, 2015, 18(3): 245-248.
    中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华肝脏病杂志, 2017, 25(12): 886-895.
    冯锐, 陶志刚, 徐后云, 等. CalliSpheres载药栓塞微球治疗肝脏乏血供恶性肿瘤短期疗效分析[J]. 临床放射学杂志, 2019, 38(6): 1107-1111.
    陈猛, 许荣德, 胡宝山, 等. HepaSphere载药微球栓塞治疗原发性肝癌的近期疗效及安全性[J]. 肿瘤防治研究, 2019, 46(7): 627-631.
    马洺远, 林纲毅, 蔡宗洋, 等. 微球经肝动脉化疗栓塞术联合放疗治疗不可切除肝癌的有效性和安全性分析[J]. 临床肝胆病杂志, 2019, 35(11): 2489-2494.
    池琦, 张玲玲, 刘彬, 等. 表柔比星分别联合碘油与Hepasphere载药微球对肝癌患者TACE的疗效分析[J]. 现代肿瘤医学, 2018, 26(13): 2090-2093.
    马明, 牛婷婷, 邵亮, 等. 肝动脉化疗栓塞术联合立体定向放疗治疗较大原发性肝癌临床研究[J]. 创伤与急危重病医学, 2017, 5(1): 32-35.
    欧盛秋, 陈祖毅, 马亦龙, 等. 阿霉素载药微球与传统的碘化油经导管动脉化疗栓塞术治疗原发性肝癌疗效的Meta分析[J]. 中国介入影像与治疗学, 2014, 11(11): 712-716.
    张纪军, 崔玉军, 蔡金贞. Embosphere微球栓塞在原发性肝癌的治疗效果及其对Th1、Th2细胞炎症因子的影响[J]. 广东医学, 2017, 38(10): 1523-1527.
    张炯善, 谢和平, 陈燕, 等. 贞芪扶正胶囊联合TACE术治疗原发性肝癌的临床观察[J]. 中药材, 2019, 42(12): 2972-2974.
    陈刚, 张鼎, 应亚草, 等. 国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J]. 浙江大学学报: 医学版, 2017, 46(1): 44-51.
    Inagaki K, Tang W, makuuchi M, et al. Clinical andmolecular insights into the hepatocellular carcinoma tumour marker des-Y-carboxyprothrombin[J]. Liver Int, 2011, 31(1): 22-35.
    Gaba RC, Emmadi R, Parvinian A, 等. 兔VX2肝肿瘤载药微球动脉化疗栓塞后阿霉素释放剂量和肿瘤坏死之间的关系[J]. 国际医学放射学杂志, 2016, 39(6): 677-678.
    • Related Articles

  • Related Articles

    [1]MIAO Rui, ZHANG Man, WANG Xuezhi, HAO Yafeng, LIN Li, QUAN Huijuan. Relationship of impaired glucose regulation with slow flow or no reflow during percutaneous coronary intervention in patients with ST segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 40-44, 51. DOI: 10.7619/jcmp.20234122
    [2]ZHANG Li, WANG Lin, HE Wei. Relationships of serum S100 calcium binding protein A8 and S100 calcium binding protein A9 levels with thrombus burden in patients with acute ST-segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 37-42. DOI: 10.7619/jcmp.20232069
    [3]ZOU Yue, CHEN Xufeng. Application of extracorporeal membrane oxygenation in high-risk percutaneous coronary intervention without obvious shock[J]. Journal of Clinical Medicine in Practice, 2022, 26(12): 139-143. DOI: 10.7619/jcmp.20220164
    [4]LIU Qi, JIA Yunshi, SONG Wenting, LI Wuwei. Effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention in low-risk non-ST-elevation acute coronary syndrome patients[J]. Journal of Clinical Medicine in Practice, 2021, 25(24): 69-73. DOI: 10.7619/jcmp.20212580
    [5]ZHANG Jiangang, DAI Shipeng, LIU Hua, MA Zengcai, LIU Juan, XU Zesheng. Effect of percutaneous coronary intervention guided by intravascular ultrasound in treatment of patientswith borderline lesions of non-ST elevated acute coronary syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 53-56. DOI: 10.7619/jcmp.20211247
    [6]LIN Lingdan, XU Shida, XING Haiyan. Value of serum interleukin-17 in predicting slow flow or no reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(11): 93-95, 100. DOI: 10.7619/jcmp.20210482
    [7]WANG Huan, WANG Haibo. Effect of ticagrelor for acute non-ST-segment elevation myocardial infarction patents underwent percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2019, 23(20): 19-21, 24. DOI: 10.7619/jcmp.201920005
    [8]ZHOU Yingfeng. Effect of atorvastatin on no-reflow phenomenon after emergency percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2019, (2): 40-43. DOI: 10.7619/jcmp.201902012
    [9]LI Wenhua, HE Guoping, LI Yong. Application value of Rho-kinase inhibitor in acute coronary syndrome patients with percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2016, (19): 12-15. DOI: 10.7619/jcmp.201619004
    [10]SANG Caidi, ZHANG Yisheng. Observation of coronary arterial injection of tirofiban on prevention of no reflow phenomenon in emergency treatment of patients with percutaneous coronary intervention and related nursing measures[J]. Journal of Clinical Medicine in Practice, 2013, (18): 60-62. DOI: 10.7619/jcmp.201318026

  • Cited by

    Periodical cited type(3)

    1. 宋尚明. 独活寄生汤联合BKA治疗中老年重度双间室膝关节骨关节炎的效果. 中国医学创新. 2024(03): 90-94 .
    2. 梁竹君，肖芮. 蠲痹汤加减治疗活动期类风湿关节炎临床观察. 山西中医. 2024(03): 16-18 .
    3. 关岳，李新，杨贺旻，徐思宇，史丽东，刘扬洋，孔令丹，秦影. IRF9、PSMA5联合外周血巨噬细胞M1/M2极化状态预测类风湿性关节炎进展的多元回归模型. 中华养生保健. 2024(19): 4-8 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (384) PDF downloads (18) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return